Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02711865

Enrollment

Registered

2016-03-17

Start date

2016-05-31

Completion date

2019-05-31

Last updated

2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.

Interventions

BIOLOGICALIGF1R antibody MK0646

OTHERSaline solution

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with ovarian cancer

Exclusion criteria

* All others

Design outcomes

Primary

Measure	Time frame	Description
Responsive to IGF1R therapy	One year	Mean tumor volume will be calculated and growth inhibition will be reported as the percentage decrease of tumor volume compared with the control.

Secondary

Measure	Time frame	Description
Proteomic Signature of IGF1R Responsive Tumors	One year	Mass Spectrometry will be used to compare IGF1R responsive and non-responsive tumors to identify the proteins associated with sensitivity to IGF1R therapy.

Countries

Israel

Contacts

Primary ContactRinat Lift, MSc

rinatl@hy.health.gov.il972-4-6304335

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026